2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working PartyMichael Heuser, Jacqueline Cloos, Marion Subklewe et al.|Blood|2021Cited by 714
Pretransplant <i>FLT3</i>-ITD MRD assessed by high-sensitivity PCR-NGS determines posttransplant clinical outcomeSun Loo, Andrew H. Wei, Richard Dillon et al.|Blood|2022Cited by 83
Molecular, clinical, and therapeutic determinants of outcome in <i>NPM1</i>-mutated AMLJad Othman, Richard Dillon, Nicola Potter et al.|Blood|2024Cited by 78
Postinduction molecular MRD identifies patients with <i>NPM1</i> AML who benefit from allogeneic transplant in first remissionJad Othman, Nigel H. Russell, Nicola Potter et al.|Blood|2024Cited by 75
Molecular MRD is strongly prognostic in patients with <i>NPM1</i>-mutated AML receiving venetoclax-based nonintensive therapyJad Othman, Richard Dillon, Ing Soo Tiong et al.|Blood|2023Cited by 65